Literature DB >> 21524955

A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G.

Jen Lim Chong1, Satwi Sapari, Yeh Chunn Kuan.   

Abstract

Influenza A "novel H1N1" with severe acute respiratory distress syndrome (ARDS) is a serious illness that poses a challenge to clinicians managing such cases. This case report reveals a patient with ARDS secondary to influenza A with deteriorating clinical status, who improved tremendously after intravenous immunoglobulin G (IV IgG). Patients with H1N1 associated with ARDS may be given a trial of IV IgG. More case reports and trials are required to ascertain the efficacy of IV IgG and the best dosage and timing of starting IV IgG in relation to antiviral therapy.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524955     DOI: 10.1016/j.jmii.2010.07.001

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  10 in total

1.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

2.  Case Report: The First Case of COVID-19 in Bhutan.

Authors:  Shankar LeVine; Guru Prasad Dhakal; Tshering Penjor; Pem Chuki; Kesang Namgyal; Melanie Watts
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

3.  Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection.

Authors:  Steven Rockman; Sue Lowther; Sarina Camuglia; Kirsten Vandenberg; Shirley Taylor; Lou Fabri; Sylvia Miescher; Martin Pearse; Deborah Middleton; Stephen J Kent; Darryl Maher
Journal:  EBioMedicine       Date:  2017-04-06       Impact factor: 8.143

4.  Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy.

Authors:  Stefanie Prohaska; Andrea Schirner; Albina Bashota; Andreas Körner; Gunnar Blumenstock; Helene A Haeberle
Journal:  J Intensive Care       Date:  2018-02-26

Review 5.  Contemporary management of severe influenza disease in the intensive care unit.

Authors:  Patrick M Wieruszewski; Dustin D Linn
Journal:  J Crit Care       Date:  2018-08-20       Impact factor: 3.425

Review 6.  Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.

Authors:  Tharmala Tharmalingam; Xiaobing Han; Ashley Wozniak; Laura Saward
Journal:  Hum Vaccin Immunother       Date:  2021-05-19       Impact factor: 4.526

7.  Severe influenza treatment guideline.

Authors:  Won Suk Choi; Ji Hyeon Baek; Yu Bin Seo; Sae Yoon Kee; Hye Won Jeong; Hee Young Lee; Byung Wook Eun; Eun Ju Choo; Jacob Lee; Young Keun Kim; Joon Young Song; Seong-Heon Wie; Jin Soo Lee; Hee Jin Cheong; Woo Joo Kim
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884

Review 8.  How to approach and treat viral infections in ICU patients.

Authors:  Theodoros Kelesidis; Ioannis Mastoris; Aliki Metsini; Sotirios Tsiodras
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.667

Review 9.  Adjunctive therapies and immunomodulating agents for severe influenza.

Authors:  David S C Hui; Nelson Lee
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

Review 10.  Adjunctive therapies and immunomodulatory agents in the management of severe influenza.

Authors:  David S Hui; Nelson Lee; Paul K Chan
Journal:  Antiviral Res       Date:  2013-04-08       Impact factor: 5.970

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.